Pirfenidone for the treatment of idiopathic pulmonary fibrosis

References

• Seto Y, Inoue R, Kato M, et al. Photosafety assessments on pirfenidone: photochemical, photobiological, and pharmacokinetic characterization. J Photochemical Photobiol B 2013;120:44-51
   PubMed Web of Science ®Google Scholar
• Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061-9
   PubMed Web of Science ®Google Scholar
• Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002;76:234-42
   PubMed Web of Science ®Google Scholar
• Nagai S, Hamada K, Shigematsu M, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002;41:1118-23
   PubMed Web of Science ®Google Scholar
• Cottin V. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res 2013;14(Suppl 1):S5
   PubMedGoogle Scholar
• Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011;20:85-97
   PubMedGoogle Scholar
• Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999;276:311-18
   PubMed Web of Science ®Google Scholar
• Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590:400-8
   PubMed Web of Science ®Google Scholar
• Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc) 2010;46:473-82
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;291:367-73
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289:211-18
   PubMed Web of Science ®Google Scholar
• Adamali HI, Maher TM. Current and novel drug therapies for idio pathic pulmonary fibrosis. Drug Des Devel Ther 2012;6:261-72
   PubMed Web of Science ®Google Scholar
• Peng ZZ, Hu GY, Shen H, et al. Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology (Carlton) 2009;14:565-72
   PubMedGoogle Scholar
• Zhao XY, Zeng X, Li XM, et al. Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin.Exp Pharmacol Physiol 2009;36:963-8
   PubMedGoogle Scholar
• Miric G, Dallemagne C, Endre Z, et al. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001;133:687-94
   PubMed Web of Science ®Google Scholar
• Togami K, Kanehira Y, Tada H. Possible involvement of pirfenidone metabolites in the antifibrotic action of therapy for idiopathic pulmonary fibrosis. Biol Pharm Bull 2013;36:1525-7
   PubMed Web of Science ®Google Scholar
• Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009;22:279-85
   PubMed Web of Science ®Google Scholar
• Taniyama M, Ohbayashi S, Narita M, et al. Pharmacokinetics of an antifibrotic agent, pirfenidone, in aemodialysis patients. Eur J Clin Pharmacol 1997;52:77-8
   PubMed Web of Science ®Google Scholar
• Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51
   PubMed Web of Science ®Google Scholar
• Antoniou KM, Margaritopoulos GA, Siafakas NM. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 2013;22:281-91
   PubMedGoogle Scholar
• Lasithiotaki I, Antoniou KM, Vlahava VM, et al. Detection of herpes simplex virus type-1 in patients with fibrotic lung diseases. PLoS One 2011;6:e27800
   PubMed Web of Science ®Google Scholar
• Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011;66:226-31
   PubMed Web of Science ®Google Scholar
• Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:1390-4
   PubMed Web of Science ®Google Scholar
• Samara KD, Margaritopoulos G, Wells AU, et al. Smoking and pulmonary fibrosis: novel insights. Pulm Med 2011;2011:461439
   PubMedGoogle Scholar
• Poletti V, Ravaglia C, Buccioli M, et al. Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. Respiration 2013;86:5-12
   PubMedGoogle Scholar
• Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007;30:835-9
   PubMed Web of Science ®Google Scholar
• Armanios M. Syndromes of telomere shortening. Annu Rev Genomics Hum Genet 2009;10:45-61
   PubMed Web of Science ®Google Scholar
• Coppe´ JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118
   PubMed Web of Science ®Google Scholar
• Chilosi M, Doglioni C, Murer B, Poletti V. Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010;27:7-18
   PubMedGoogle Scholar
• Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178:838-46
   PubMed Web of Science ®Google Scholar
• Lawson WE, Cheng DS, Degryse AL, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA 2011;108:10562-7
   PubMed Web of Science ®Google Scholar
• Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 2010;181:254-63
   PubMed Web of Science ®Google Scholar
• Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res 2013;162:156-73
   PubMed Web of Science ®Google Scholar
• Richter AG, McKeown S, Rathinam S, et al. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009;64:156-61
   PubMed Web of Science ®Google Scholar
• Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008;133:226-32
   PubMed Web of Science ®Google Scholar
• Gunther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000;83:853-60
   PubMed Web of Science ®Google Scholar
• Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004;170:242-51
   PubMed Web of Science ®Google Scholar
• Chilosi M, Zamò A, Doglioni C, et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res 2006;7:95
   PubMed Web of Science ®Google Scholar
• Nakayama S, Mukae H, Sakamoto N, et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 2008;82:210-17
   PubMed Web of Science ®Google Scholar
• Tian XL, Yao W, Guo ZJ, et al. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. Chin Med Sci J 2006;21:145-51
   PubMedGoogle Scholar
• Spond J, Case N, Chapman RW, et al. Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulm Pharmacol Ther 2003;16:207-14
   PubMed Web of Science ®Google Scholar
• Raghu G, Thickett DR. Pirfenidone for IPF: pro/con debate; the ’con’ viewpoint. Thorax 2013;68:605-8
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respi Crit Care Med 2005;171:1040-7
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R, et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8
   PubMed Web of Science ®Google Scholar
• King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-c1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-7
   PubMed Web of Science ®Google Scholar
• Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-7
   PubMed Web of Science ®Google Scholar
• King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-81
   PubMed Web of Science ®Google Scholar
• Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42
   PubMed Web of Science ®Google Scholar
• Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests. Reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:1150-7
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9
   PubMed Web of Science ®Google Scholar
• Behr J. Evidence-based treatment strategies in idiopathic pulmonary fibrosis. Eur Respir Rev 2013;22:163-8
   PubMedGoogle Scholar
• Costabel U, Albera C, Cohen A. The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): interim data from the RECAP extension study [abstract 174]. Presented at the European Respiratory Society Annual Congess; 24-29 September 2011. Amsterdam, The Netherlands
   Google Scholar
• Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010;9:CD003134
   Google Scholar
• Albera C, Ferrero C, Rindone E, et al. Where do we stand with IPF treatment? Respir Res 2013;14(Suppl 1):S7
   PubMedGoogle Scholar
• IQWiG. Available from: www.iqwig.de/pirfenidone-extent-of-added-benefit-assessed.1391.en.html
   Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01366209
   Google Scholar
• Guyatt G, Gutterman D, Baumann NH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 2006;129:174-81
   PubMed Web of Science ®Google Scholar
• Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respr Crit Care Med 2006;174(5):605-14
   Google Scholar
• Schunemann HJ, Jaeschke R, Cook DJ, et al. ATS Documents Development and Implementation Committee. ATS/ERS/JRS/ALAT: an Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines For Diagnosis and Management. Am J Respir Crit Care Med 2011;183:788-824
   PubMedGoogle Scholar
• Behr J, Richeldi L. Recommendations in treatment of IPF. Respir Res 2013;14(Suppl 1):S6
   PubMedGoogle Scholar
• Behr J, Günther A, Ammenwerth W, et al. German guideline for diagnosis and management of idiopathic pulmonary fibrosis. Pneumologie 2013;67:81-111
   PubMedGoogle Scholar
• Cottin V. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir Rev 2012;21:161-7
   PubMedGoogle Scholar
• MarketWatch. Available from: www.marketwatch.com/story/esbriet-pirfenidone-benefit-granted-bygerman-federal-joint-committee-g-ba-2012-03-15
   Google Scholar
• Sverzellati N, Wells AU, Tomassetti S, et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology 2010;254:957-64
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9
   PubMed Web of Science ®Google Scholar